Argent BioPharma Ltd (RGTLF)
Argent BioPharma Ltd is a clinical-stage biopharmaceutical company listed on OTC Markets as common stock. The company develops nano-engineered therapeutics aimed at influencing the balance between the nervous and immune systems, with operations and development activities in Malta, Slovenia, Australia, and other international markets. Its pipeline includes CimetrA, a phase III candidate for acute lung injury and ARDS; CannEpil, a phase I program for refractory epilepsy; and CogniCann, which is in phase IIA development for the symptomatic relief of dementia and Alzheimer’s. Argent BioPharma is also advancing Irnican in preclinical work for glioblastoma multiforme and conducts research focused on wound treatment. The company has also worked with SINTEF on antimicrobial therapies for chronic wounds and potential applications in oncologic wound care. Founded in 2014 and based in Subiaco, Australia, it was previously known as MGC Pharmaceuticals Limited.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-RGTL.F
|
—
|
—
|
—
|
—
|
—
|
—
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 28, 2026
|
-0.7x
|
-0.7x
|
17.3x
|
4.212 M
|
8.053 M
|
58.2%
|
34.4%
|
-298.0
|
—
|
88.3%
|
